Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
84.49
-4.22 (-4.76%)
At close: Nov 4, 2025, 4:00 PM EST
79.40
-5.09 (-6.02%)
After-hours: Nov 4, 2025, 7:59 PM EST
Tempus AI Revenue
Tempus AI had revenue of $334.21M in the quarter ending September 30, 2025, with 84.72% growth. This brings the company's revenue in the last twelve months to $1.11B, up 72.58% year-over-year. In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth.
Revenue (ttm)
$1.11B
Revenue Growth
+72.58%
P/S Ratio
13.13
Revenue / Employee
$460,524
Employees
2,400
Market Cap
14.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
TEM News
- 6 hours ago - Tempus AI, Inc. (TEM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 9 hours ago - Tempus Reports Third Quarter 2025 Results - Business Wire
- 7 days ago - Tempus to Participate in the Stifel 2025 Healthcare Conference - Business Wire
- 14 days ago - Tempus to Report Third Quarter 2025 Financial Results on November 4 - Business Wire
- 15 days ago - Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity - Business Wire
- 19 days ago - Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research - Business Wire
- 20 days ago - Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 - Business Wire
- 26 days ago - Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy - Business Wire